ES2076981T3 - Polipeptido fisiologicamente activo y adn. - Google Patents

Polipeptido fisiologicamente activo y adn.

Info

Publication number
ES2076981T3
ES2076981T3 ES90104021T ES90104021T ES2076981T3 ES 2076981 T3 ES2076981 T3 ES 2076981T3 ES 90104021 T ES90104021 T ES 90104021T ES 90104021 T ES90104021 T ES 90104021T ES 2076981 T3 ES2076981 T3 ES 2076981T3
Authority
ES
Spain
Prior art keywords
edema
physiologically active
activity
polypeptide
active polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90104021T
Other languages
English (en)
Other versions
ES2076981T5 (es
Inventor
Tetsuji Sudoh
Keiji Maekawa
Naoto Minamino
Kenji Kangawa
Hisayuki Matsuo
Atsushi Izumi
Mika Takashima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Sekisui Medical Co Ltd
Original Assignee
Daiichi Pure Chemicals Co Ltd
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26390052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2076981(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP04963689A external-priority patent/JP3160276B2/ja
Priority claimed from JP1059183A external-priority patent/JP2883903B2/ja
Application filed by Daiichi Pure Chemicals Co Ltd, Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pure Chemicals Co Ltd
Publication of ES2076981T3 publication Critical patent/ES2076981T3/es
Application granted granted Critical
Publication of ES2076981T5 publication Critical patent/ES2076981T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE PRESENTA UN POLIPEPTIDO FISIOLOGICAMENTE ACTIVO DERIVADO DEL CEREBRO HUMANO Y UN FRAGMENTO DE DNA QUE COMPRENDE LA SECUENCIA BASE QUE CODIFICA EL POLIPEPTIDO. EL POLIPEPTIDO POSEE UNA ACTIVIDAD DE RELAJACION MUSCULAR EXCELENTE Y SUAVE, ACTIVIDAD DIURETICA O NATRIURETICA, ACTIVIDAD VASODEPRESORA, Y ES UTIL COMO MEDICAMENTO PARA LA CURACION DE ENFERMEDADES CIRCULATORIAS, POR EJEMPLO EDEMA CARDIACO, EDEMA NEFRITICO, EDEMA HEPATICO, EDEMA PULMONAR, HIPERTENSION, FALLO DE CALOR CONGESTIVO, Y FALLO RENAL CRONICO O AGUDO.
ES90104021T 1989-03-01 1990-03-01 Polipeptido fisiologicamente activo y su adn. Expired - Lifetime ES2076981T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP04963689A JP3160276B2 (ja) 1989-03-01 1989-03-01 新規ｃＤＮＡフラグメント
JP1059183A JP2883903B2 (ja) 1989-03-10 1989-03-10 新規生理活性ペプチド及びその用途

Publications (2)

Publication Number Publication Date
ES2076981T3 true ES2076981T3 (es) 1995-11-16
ES2076981T5 ES2076981T5 (es) 2000-02-01

Family

ID=26390052

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90104021T Expired - Lifetime ES2076981T5 (es) 1989-03-01 1990-03-01 Polipeptido fisiologicamente activo y su adn.

Country Status (6)

Country Link
EP (1) EP0385476B2 (es)
AT (1) ATE124994T1 (es)
CL (1) CL2004001266A1 (es)
DE (1) DE69020755T3 (es)
DK (1) DK0385476T4 (es)
ES (1) ES2076981T5 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211686D0 (en) * 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
US5665704A (en) * 1993-11-12 1997-09-09 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5846932A (en) * 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US6525022B1 (en) 1993-11-12 2003-02-25 Genentech, Inc. Receptor specific atrial natriuretic peptides
US6028055A (en) * 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
WO2000018422A1 (fr) * 1998-09-28 2000-04-06 Santen Pharmaceutical Co., Ltd. Promoteurs de secretion lacrymale ou gouttes ophtalmologiques contenant des peptides natriuretiques comme principes actifs pour traiter la keratoconjonctivite
WO2004047871A2 (en) 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
EP2004633A4 (en) 2006-03-30 2009-08-26 Palatin Technologies Inc LINEAR NATRIURETIC PEPTIDE CONSTRUCTS
CA2647143A1 (en) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
US8580746B2 (en) 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
US20100204145A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of a peptide as a therapeutic agent
PL409596A1 (pl) * 2014-09-25 2016-03-29 Uniwersytet Wrocławski Pochodne pseudofaktyny, sposób otrzymywania pochodnych pseudofaktyny oraz ich zastosowanie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
EP0385476B1 (en) 1995-07-12
DE69020755T3 (de) 2000-03-02
DK0385476T4 (da) 1999-12-20
EP0385476A1 (en) 1990-09-05
DE69020755D1 (de) 1995-08-17
EP0385476B2 (en) 1999-09-22
DE69020755T2 (de) 1996-04-04
CL2004001266A1 (es) 2005-02-04
ES2076981T5 (es) 2000-02-01
DK0385476T3 (da) 1995-10-02
ATE124994T1 (de) 1995-07-15

Similar Documents

Publication Publication Date Title
ES2076981T3 (es) Polipeptido fisiologicamente activo y adn.
BR9714363A (pt) Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas
MX27046A (es) 5-arilalquil-4-alcoxy-2(5h)-furanonas, productos intermedios y procedimiento para su preparacion asi como su aplicacion como sustancia activa terapeutica.
FI851336A0 (fi) Ny fysiologiskt aktiv human polypeptid.
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
ATE358176T1 (de) Menschliche dnase
ES2060033T3 (es) Un procedimiento para preparar un polipeptido de fusion.
DK0480934T3 (da) Lægemiddel, der indeholder ephedrin og koffein til behandling af overvægt
MXPA03006855A (es) Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion.
DK215287A (da) Dna-sekvenser, der koder for et protein med angiogen virkning, vektorer, vaertsceller og fremgangsmaader til udtrykkelse af proteinet, samt laegemidler indeholdende dette
PT998287E (pt) Utilizacao de levobupivacaina
ES2037792T3 (es) Un metodo para prevenir que se formen coagulos de sangre en el circuito extracorporal de un aparato de dialisis y una composicion util del mismo.
ES2118057T3 (es) Factor de crecimiento nervioso humano.
ES2168361T3 (es) Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo.
GR1002847B (el) Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
GR3006089T3 (es)
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
ES2148283T3 (es) Gen merlin supresor de tumores y usos del mismo.
Cheng The treatment of headaches employing acupuncture
EP0795332A3 (en) Medical use of gamma-interferon in interstitial lung diseases
ES2138602T3 (es) Agente terapeutico para la amenaza de aborto.
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
NO179855C (no) Fremgangsmåte for fremstilling av et legemiddel
NZ513087A (en) Bactericidal/permability -increasing protein (BPI) for treating chronic heart disease
ATE203680T1 (de) Konjugat zur behandlung von entzündungserkrankungen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 385476

Country of ref document: ES